Login to Your Account



Lone responder in Rigel placebo set turns phase III, but plan intact

By Randy Osborne
Staff Writer

Thursday, October 20, 2016

What one analyst characterized as a "weird" placebo response in one patient was enough to skew the results for Rigel Pharmaceuticals Inc.'s second of two double-blind studies in its FIT phase III program with fostamatinib.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription